Mineralys Therapeutics Inc

Mineralys Therapeutics Inc is a clinical-stage biotechnology company that is engaged in the development of novel therapies for patients with hypertension, Chronic Kidney Disease (CKD) and other related diseases. Operating in the biopharmaceutical sector, Mineralys’ primary focus is designing safe and effective medications to combat conditions linked to excess aldosterone. Its primary candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI). Stay up to date on the share price of MLYS by adding it to your eToro watchlist.